Showing results (201-210 of 226) with videos related to

Sort By:
Pageof 23
Proceedings of the National Academy of Sciences of the United States of America|August 30, 1994
Transthyretin sequesters amyloid beta protein and prevents amyloid formationA L Schwarzman, L Gregori, M P Vitek, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|March 15, 2021
Early MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS studyMark S Freedman, Patricia K Coyle, Giancarlo Comi, et al.
Neurology and Therapy|January 11, 2024
Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary PerspectivesMark S Freedman, Patricia K Coyle, Kerstin Hellwig, et al.
Neurology|April 6, 2000
A phase I trial of solubilized DR2:MBP84-102 (AG284) in multiple sclerosisD E Goodkin, M Shulman, J Winkelhake, et al.
Multiple Sclerosis and Related Disorders|December 16, 2021
Discontinuation of disease modifying therapies is associated with disability progression regardless of prior stable disease and ageDejan Jakimovski, Katelyn S Kavak, Caila B Vaughn, et al.
BMC Neurology|October 7, 2020
Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosisGiancarlo Comi, Mark S Freedman, José E Meca-Lallana, et al.
Plos One|September 17, 2013
Gray matter is targeted in first-attack multiple sclerosisSteven E Schutzer, Thomas E Angel, Tao Liu, et al.
International Journal of MS Care|December 23, 2017
Fatigue and Mood States in Nursing Home and Nonambulatory Home-Based Patients with Multiple SclerosisZilfah Younus, Caila B Vaughn, Shaik Ahmed Sanai, et al.
Neurology|January 3, 2001
Are quantitative functional measures more sensitive to worsening MS than traditional measures?S R Schwid, A D Goodman, B R Apatoff, et al.
Pageof 23